MedTrace Logo

Impact of the Artificial Intelligence in a Telemonitoring Programme of COPD Patients With Multiple Hospitalizations

NCT04978922 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2021-07-27

No results posted yet for this study

Summary

Given the current situation concerning healthcare, population demographics and economy, it seems required to look for new approaches in the health system. The use of new technologies must be the main factor for this change.

GENERAL OBJECTIVE:

To determine the impact that the application of an artificial intelligence system (Machine Learning) could have on an active telemonitoring programme of readmitted COPD patients.

Particular objectives: to determine the changes in:

* The use of healthcare resources.
* Patients´ quality of life.
* Costs.
* Load of work.
* Daily clinical practice.
* Inflammation markers

METHODS:

Based on the telEPOC programme and Machine Learning developement in this project, non-randomized intervention study, with two branches: intervention (Galdakao hospital) and control (Cruces and Basurto hospital).

Sample size of at least 115 patients per hospital (115 in the intervention branch and 230 in the control branch). A 2-year follow-up.

Uni and multivariate statistics will be applied.

Conditions

Interventions

DEVICE

Machine Learning: ML (Artificial Intelligence System)

To applicate an artificial intelligence system (Machine Learning: ML) on an active telemonitoring programme of readmitted COPD patients (TelEPOC)

Sponsors & Collaborators

  • Osakidetza

    collaborator OTHER

  • Dr. Cristobal Esteban

    lead OTHER_GOV

Principal Investigators

  • Cristobal Esteban, MD · Osakidetza

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2022-01-01
Completion
2022-06-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04978922 on ClinicalTrials.gov